Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates

分组1 - Amicus Therapeutics reported quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of$0.10 per share, compared to a loss of $0.11 per share a year ago, representing an earnings surprise of -10$149.71 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.13%, and this is an increase from year-ago revenues of $115.08 million [2] - The current consensus EPS estimate for the coming quarter is$0.07 on revenues of $141.25 million, and for the current fiscal year, it is$0.43 on revenues of $638.94 million [7] 分组2 - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the top 28% of over 250 Zacks industries, indicating that the industry is performing well [8] - Amicus Therapeutics has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] - The stock has added about 3.7% since the beginning of the year, compared to the S&P 500's gain of 4% [3]